Clevudine

CHF 40.00
In stock
AG-CR1-3736-M0055 mgCHF 40.00
AG-CR1-3736-M01010 mgCHF 60.00
AG-CR1-3736-M05050 mgCHF 180.00
More Information
Product Details
Synonyms Levovir; L-FMAU; 2'-Fluoro-5-methyl-β-L-arabinofuranosyl-uracil
Product Type Chemical
Properties
Formula

C10H13FN2O5

MW 260.2
CAS 163252-36-6
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in water (30mg/ml) or DMSO (20mg/ml).
Identity Determined by 1H-NMR.
InChi Key GBBJCSTXCAQSSJ-XQXXSGGOSA-N
Smiles O[C@H]1[C@H](CO)O[C@]([H])(N2C=C(C)C(NC2=O)=O)[C@@H]1F
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Clevudine is a synthetic pyrimidine nucleoside analog antiviral agent with activity against hepatitis B virus (HBV) and Epstein-Barr virus (EBV). 
  • Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase and reverse transcriptase, consequently blocking the viral replication. It also blocks the DNA supply of the virus into the nucleus, reducing the amount of cccDNA by 20-100 times.
  • Potentially useful for the treatment of the SARS-CoV-2 (COVID-19) infection, acting as a potent inhibitor of the RdRp protein.
Product References
  1. Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus: C.K. Chu, et al.; Antimicrob. Agents Chemother. 39, 979 (1995)
  2. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax): S.F. Peek, et al.; Hepatology 33, 254 (2001)
  3. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies: Y. Chong & C.K. Chu; Bioorg. Med. Chem. Lett. 12, 3459 (2002)
  4. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells: R. Hu, et al.; Antimicrob. Agents Chemother. 49, 2044 (2005)
  5. Clevudine for the treatment of chronic hepatitis B virus infection: C.K. Hui & G.K. Lau; Expert Opin. Investig. Drugs 14, 1277 (2005) (Review)
  6. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo: B.E. Korba, et al.; Expert Rev. Anti. Infect. Ther. 4, 549 (2006) (Review)
  7. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes: C. Niu, et al.; Antivir. Ther. 13, 263 (2008)
  8. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors: C. Niu, et al.; Antivir. Ther. 15, 401 (2010)
  9. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine: S.A. Jones, et al.; Antimicrob. Agents Chemother. 57, 4181 (2013)
  10. Identification of Potent Drugs and Antiviral Agents for the Treatment of the SARS-CoV-2 Infection: N.R. Jena; ChemRxiv (Preprint) (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.